Unity Biotechnology (UBX) shares were down nearly 30% in recent trading on Monday after the company said UBX1325, its diabetic macular edema treatment for patients with poor vision, did not achieve statistical non-inferiority at the primary analysis endpoint in the phase 2b Aspire study.
The company said UBX1325 was non-inferior to aflibercept at week 24 with a confidence interval above 90% but did not meet statistical non-inferiority on the average of weeks 20 and 24, reaching an 88% confidence interval instead of the pre-specified 90% threshold.
Unity Biotechnology posted topline results from all participants through 24 weeks and expects complete 36-week data results in Q2.
Price: 1.28, Change: -0.55, Percent Change: -29.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。